ArticleJournal of perinatology : official journal of the California Perinatal Association2005
Single-dose darbepoetin administration to anemic preterm neonates.
Article in Journal of perinatology : official journal of the California Perinatal Association, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00334737 (A Randomized, Masked, Placebo Controlled Study to Assess the Safety and Efficacy of Darbepoetin Alfa Administered to Preterm Infants), which is not on this map. Cited by 24 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Masked, Placebo Controlled Study to Assess the Safety and Efficacy of Darbepoetin Alfa Administered to Preterm Infants
Who cites it
24 citing papers in PubMed, 6 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Early erythropoiesis-stimulating agents in preterm or low-birthweight infants.The Cochrane database of systematic reviews · 2026Pooled it
- Early erythropoiesis-stimulating agents in preterm or low birth weight infants.The Cochrane database of systematic reviews · 2020Pooled it
- Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.The Cochrane database of systematic reviews · 2020Pooled it
- Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.The Cochrane database of systematic reviews · 2020Pooled it
- Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.The Cochrane database of systematic reviews · 2019Pooled it
- Early erythropoiesis-stimulating agents in preterm or low birth weight infants.The Cochrane database of systematic reviews · 2017Pooled it
- A prospective randomized pilot trial comparing weekly vs. biweekly Darbepoetin administration to preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2025Trial
- Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing.Journal of pharmaceutical sciences · 2017Trial
- Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy.Clinical pharmacokinetics · 2015Trial
- Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial.Pediatric research · 2015Trial
- Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo.Pediatrics · 2014Trial
- A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants.Pediatrics · 2013Trial
- Very low birth weight infants qualifying for a 'late' erythrocyte transfusion: does giving darbepoetin along with the transfusion counteract the transfusion's erythropoietic suppression?Journal of perinatology : official journal of the California Perinatal Association · 2011Trial
- Intravenous administration of darbepoetin to NICU patients.Journal of perinatology : official journal of the California Perinatal Association · 2006Trial
- Article
- Development of an electrochemiluminescence assay to measure serum darbepoetin concentration in extremely preterm infants.Bioanalysis · 2025Article
- Free Radicals and Neonatal Brain Injury: From Underlying Pathophysiology to Antioxidant Treatment Perspectives.Antioxidants (Basel, Switzerland) · 2021Review
- Darbepoetin Administration in Term and Preterm Neonates.Clinics in perinatology · 2015Review
- Why do four NICUs using identical RBC transfusion guidelines have different gestational age-adjusted RBC transfusion rates?Journal of perinatology : official journal of the California Perinatal Association · 2015Article
- Estimating the nucleated red blood cell 'emergence time' in neonates.Journal of perinatology : official journal of the California Perinatal Association · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDarbepoetin is longer acting and more potent than recombinant erythropoietin (rEpo). In certain situations, preterm neonates might benefit from rEpo, and for such patients darbepoetin would require fewer doses at a lower cost. However, the proper dose and dosing interval have not been established. STUDY
designWe performed a prospective trial in two level III Neonatal Intensive Care Units. Patients <32 weeks gestation at birth, with a birth weight (BW) <1500 g, were eligible for participation if they were >21-days-old and had a hemoglobin (Hgb) concentration </or=10.5 g/dl. In all, 12 were to receive a single subcutaneous (s.c.) dose at either 1 or 4 microg/kg. Once before the dose was given, and at two preset intervals after, blood was obtained for immature reticulocyte fraction (IRF) and absolute reticulocyte count (ARC). Once before and at four preset intervals after, blood was obtained for pharmacokinetic studies.
resultsThe 12 subjects had BWs of 1129+/-245 g (mean+/-SD), were 29.2+/-1.2 weeks gestation at delivery, and were 43+/-12 days old with an Hgb concentration of 9.6+/-1.0 g/dl when the darbepoetin was given. Six received 1 microg/kg and six 4 microg/kg. The IRF increased (p<0.05) as did the ARC (p<0.05). The increases in IRF were somewhat greater among the 4 microg/kg recipients (P=0.06). The highest recorded concentrations of drug occurred 6 to 12 hours after administration. The combined 6 and 12 hours values were 185+/-106 mU/ml in the 1 microg/kg group vs 597+/-238 in the 4 microg/kg group (p<0.002). The t(1/2) was 26 hours (range 10 to 50). The biovailability-normalized clearance was 19 ml/hour/kg (range 5 to 54).
conclusionsA single s.c. dose of darbepoetin given to preterm neonates accelerated effective erythropoiesis. The pharmacodynamic and pharmacokinetic findings suggest that darbepoetin dosing in neonates would require a higher unit dose/kg and a shorter dosing interval than are generally used for anemic adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.